Today, the Chief Science of Hemispherx Biopharma Inc (HEB), David Strayer, bought shares of HEB for $9,998.
Following this transaction David Strayer’s holding in the company was increased by 84.42% to a total of $21.57K. In addition to David Strayer, 5 other HEB executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Hemispherx Biopharma Inc has an average volume of 201K.
The insider sentiment on Hemispherx Biopharma Inc has been positive according to 26 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen.
